Market Summary
USD149.67+4.20
Market Closed2.89%
SRPT Stock Price
SRPT RSI Chart
SRPT Valuation
SRPT Price/Sales (Trailing)
SRPT Profitability
SRPT Fundamentals
SRPT Revenue
SRPT Earnings
Price Action
52 Week Range
61.28159.84
(Low)(High)
Last 7 days
-4.9%
Last 30 days
21.0%
Last 90 days
16.7%
Trailing 12 Months
91.0%
SRPT Financial Health
SRPT Investor Care
Peers (Alternatives to Sarepta Therapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
BGNE | 304.8B | 1.4B | -3.73% | 61.04% | -152.12 | 215.28 | 20.37% | -37.45% |
ABBV | 275.0B | 58.1B | 0.21% | 1.63% | 23.24 | 4.74 | 3.30% | 2.55% |
REGN | 80.1B | 12.2B | -0.48% | 14.17% | 18.47 | 6.58 | -24.26% | -46.28% |
VRTX | 77.3B | 8.9B | -1.64% | 19.14% | 23.26 | 8.65 | 17.91% | 41.84% |
ALNY | 23.5B | 1.0B | -16.46% | 21.47% | -20.78 | 22.66 | 22.88% | -32.64% |
SRPT | 13.2B | 933.0M | 21.02% | 90.98% | -18.71 | 14.11 | 32.93% | -67.99% |
UTHR | 10.1B | 1.9B | -15.04% | 21.63% | 13.93 | 5.23 | 14.88% | 52.86% |
| MID-CAP | ||||||||
MDGL | 4.5B | 504.0K | -6.48% | 165.34% | -15.07 | 2.5K | -66.53% | -22.12% |
RARE | 2.8B | 363.3M | -7.03% | -36.05% | -3.99 | 7.77 | 3.39% | -55.81% |
BPMC | 2.7B | 204.0M | 2.71% | -22.88% | -4.84 | 13.22 | 13.30% | 13.44% |
MRTX | 2.5B | 12.4M | -10.70% | -44.17% | -3.35 | 199.44 | - | -27.34% |
| SMALL-CAP | ||||||||
CPRX | 1.6B | 191.8M | -7.72% | 90.19% | 24.49 | 8.55 | 43.59% | 60.82% |
MGNX | 429.6M | 93.0M | -0.16% | -22.78% | -2.25 | 4.62 | -19.83% | -30.37% |
CRBP | 24.0M | - | -31.83% | 665.59% | -0.57 | 19.11 | -77.61% | 7.22% |
CYTK | 3.5M | 94.6M | -15.04% | 9.81% | -0.01 | 0.04 | 34.30% | -80.65% |
Financials for Sarepta Therapeutics
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 6.5% | 933,013,000 | 876,047,000 | 835,184,000 | 765,786,000 | 701,887,000 |
| S&GA Expenses | 10.4% | 451,421,000 | 408,998,000 | 365,338,000 | 283,369,000 | 282,660,000 |
| Costs and Expenses | 4.1% | 1,469,214,000 | 1,411,228,000 | 1,273,468,000 | 1,160,512,000 | 1,161,597,000 |
| EBITDA | 1.3% | -603,681,000 | -611,595,000 | -404,838,000 | -252,225,000 | - |
| EBITDA Margin | 7.3% | -0.65 | -0.70 | -0.48 | -0.33 | - |
| Earnings Before Taxes | 2.9% | -689,963,000 | -710,546,000 | -502,035,000 | -355,701,000 | -418,948,000 |
| EBT Margin | 8.8% | -0.74 | -0.81 | -0.60 | -0.46 | - |
| Interest Expenses | -22.7% | 44,418,000 | 57,495,000 | 55,949,000 | 55,949,000 | 55,949,000 |
| Net Income | 1.8% | -703,488,000 | -716,225,000 | -506,631,000 | -356,555,000 | -418,780,000 |
| Net Income Margin | 7.8% | -0.75 | -0.82 | -0.61 | -0.47 | - |
| Free Cahsflow | -24.0% | -356,170,000 | -287,346,000 | -347,721,000 | -386,868,000 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | -0.9% | 3,128 | 3,156 | 2,997 | 3,056 | 3,148 |
| Current Assets | -2.6% | 2,558 | 2,626 | 2,469 | 2,531 | 2,604 |
| Cash Equivalents | -6.9% | 967 | 1,039 | 869 | 1,234 | 2,116 |
| Inventory | -7.8% | 204 | 221 | 208 | 199 | 186 |
| Net PPE | -0.5% | 180 | 181 | 183 | 187 | 191 |
| Liabilities | 0.7% | 2,743 | 2,725 | 2,270 | 2,199 | 2,220 |
| Current Liabilities | 2.8% | 620 | 603 | 546 | 455 | 453 |
| Shareholder's Equity | -10.7% | 385 | 431 | 726 | 857 | 928 |
| Retained Earnings | -2.9% | -3,910 | -3,800 | -3,543 | -3,311 | -3,206 |
| Additional Paid-In Capital | 1.5% | 4,297 | 4,235 | 4,272 | 4,169 | 4,135 |
| Shares Outstanding | 0.2% | 88.00 | 88.00 | 88.00 | 87.00 | 87.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -24.0% | -325 | -262 | -321 | -363 | -443 |
| Share Based Compensation | 9.8% | 233 | 212 | 189 | 115 | 114 |
| Cashflow From Investing | 1.2% | -1,046 | -1,059 | -1,058 | -447 | 495 |
| Cashflow From Financing | -69.8% | 233 | 771 | 560 | 564 | 562 |
Risks for SRPT
What is the probability of a big loss on SRPT?
89.2%
Probability that Sarepta Therapeutics stock will be more than 20% underwater in next one year
81.2%
Probability that Sarepta Therapeutics stock will be more than 30% underwater in next one year.
39.2%
Probability that Sarepta Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SRPT drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Sarepta Therapeutics was unfortunately bought at previous high price.
Drawdowns
Returns for SRPT
Cumulative Returns on SRPT
16.3%
10-Year Cumulative Returns
39.0%
7-Year Cumulative Returns
12.5%
5-Year Cumulative Returns
13.4%
3-Year Cumulative Returns
What are the long-term rolling returns for SRPT?
FIve years rolling returns for Sarepta Therapeutics.
Annualized Returns
Which funds bought or sold SRPT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -70.84 | -14,294,000 | 7,421,950 | 0.01% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | 3,786 | 25,786 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -73.49 | -575,000 | 259,000 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | new | - | 1,000 | 1,000 | -% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | unchanged | - | 1,662 | 11,662 | 0.01% |
2023-02-28 | Voya Investment Management LLC | added | 24.24 | 2,403,420 | 7,668,420 | 0.01% |
2023-02-24 | SRS Capital Advisors, Inc. | unchanged | - | -56.00 | 1,944 | -% |
2023-02-24 | NATIXIS | reduced | -21.99 | -1,301,070 | 13,903,900 | 0.08% |
2023-02-21 | Empowered Funds, LLC | new | - | 3,010,790 | 3,010,790 | 0.20% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -21.2 | -379,000 | 3,318,000 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Sarepta Therapeutics News
Schedule 13G FIlings of Sarepta Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | sands capital management, llc | 2.5% | 2,151,378 | SC 13G/A | |
| Feb 10, 2023 | janus henderson group plc | 6.9% | 6,028,016 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.15% | 8,033,264 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 6.3% | 5,557,234 | SC 13G/A | |
| Feb 14, 2022 | sands capital management, llc | 6.16% | 5,364,627 | SC 13G | |
| Feb 11, 2022 | janus henderson group plc | 8.3% | 7,245,862 | SC 13G | |
| Feb 10, 2022 | vanguard group inc | 9.54% | 8,311,108 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 6.1% | 5,285,234 | SC 13G/A | |
| Aug 10, 2021 | capital research global investors | 4.8% | 3,842,491 | SC 13G/A |
SRPT Fair Value
Sarepta Therapeutics fair value in different scenarios
The table shows the Fair Value estimates for Sarepta Therapeutics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 1.77 -98.82% | 3.92 -97.38% | 10.58 -92.93% | 23.14 -84.54% | 48.53 -67.58% |
| Current Inflation | 1.61 -98.92% | 3.53 -97.64% | 9.30 -93.79% | 20.03 -86.62% | 41.62 -72.19% |
| Very High Inflation | 1.42 -99.05% | 3.04 -97.97% | 7.78 -94.80% | 16.42 -89.03% | 33.66 -77.51% |
Historical Sarepta Therapeutics Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Sarepta Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 10, 2023 | 4 | Insider Trading | |
| Mar 10, 2023 | 4 | Insider Trading | |
| Mar 10, 2023 | 4 | Insider Trading | |
| Mar 10, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for SRPT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-08 | Estepan Ian Michael | sold (taxes) | -113,973 | 153 | -744 | chief financial officer |
2023-03-08 | Brown Ryan Edward | sold (taxes) | -97,275 | 153 | -635 | svp, general counsel |
2023-03-08 | Arif Bilal | sold (taxes) | -48,101 | 153 | -314 | chief tech ops officer |
2023-03-08 | Rodino-Klapac Louise | sold (taxes) | -139,709 | 153 | -912 | head of r&d, cso |
2023-03-06 | Mayo Stephen | acquired | - | - | 1,523 | - |
2023-03-06 | Nicaise Claude | acquired | - | - | 1,523 | - |
2023-03-06 | Rodino-Klapac Louise | acquired | - | - | 4,500 | head of r&d, cso |
2023-03-06 | Wigzell Hans Lennart Rudolf | acquired | - | - | 1,523 | - |
2023-03-06 | Arif Bilal | acquired | - | - | 4,500 | chief tech ops officer |
2023-03-06 | Estepan Ian Michael | sold (taxes) | -215,378 | 157 | -1,370 | chief financial officer |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
SRPT Income Statement
2022-12-31Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||||
|---|---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |||
| Revenues: | |||||
| Products, net | $ 843,769 | $ 612,401 | $ 455,865 | ||
| Type of Revenue [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember | ||
| Collaboration and other | $ 89,244 | $ 89,486 | $ 84,234 | ||
| Total revenues | 933,013 | 701,887 | 540,099 | ||
| Cost and expenses: | |||||
| Cost of sales (excluding amortization of in-licensed rights) | 139,989 | 97,049 | 63,382 | ||
| Research and development | 877,090 | 771,182 | 722,343 | ||
| Selling, general and administrative | 451,421 | 282,660 | 317,875 | ||
| Settlement and license charges | 0 | 10,000 | 0 | ||
| Amortization of in-licensed rights | 714 | 706 | 662 | ||
| Total cost and expenses | 1,469,214 | 1,161,597 | 1,104,262 | ||
| Operating loss | (536,201) | (459,710) | (564,163) | ||
| Other (loss) income, net: | |||||
| Loss on debt extinguishment | (125,441) | 0 | 0 | ||
| Gain (loss) on contingent consideration, net* | [1] | 6,700 | 7,200 | (45,000) | |
| Gain from sale of Priority Review Voucher | 0 | 102,000 | 108,069 | ||
| Other expense, net | (35,021) | (68,438) | (51,971) | ||
| Total other (loss) income, net | (153,762) | 40,762 | 11,098 | ||
| Loss before income tax (benefit) expense | (689,963) | (418,948) | (553,065) | ||
| Income tax expense (benefit) | 13,525 | (168) | 1,063 | ||
| Net loss | (703,488) | (418,780) | (554,128) | ||
| Other comprehensive loss: | |||||
| Unrealized losses on investments, net of tax | (1,644) | (23) | (47) | ||
| Total other comprehensive loss | (1,644) | (23) | (47) | ||
| Comprehensive loss | $ (705,132) | $ (418,803) | $ (554,175) | ||
| Net loss per share - basic and diluted | $ (8.03) | $ (5.15) | $ (7.11) | ||
| Net loss per share - basic and diluted | $ (8.03) | $ (5.15) | $ (7.11) | ||
| Weighted average number of shares of common stock used in computing basic and diluted net loss per share | 87,559,000 | 81,262,000 | 77,956,000 | ||
| Weighted average number of shares of common stock used in computing basic and diluted net loss per share | 87,559,000 | 81,262,000 | 77,956,000 | ||
| |||||
SRPT Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 966,777 | $ 2,115,869 |
| Short-term investments | 1,022,597 | 0 |
| Accounts receivable | 214,628 | 152,990 |
| Inventory | 203,968 | 186,212 |
| Other current assets | 149,891 | 149,028 |
| Total current assets | 2,557,861 | 2,604,099 |
| Property and equipment, net | 180,037 | 191,156 |
| Intangible assets, net | 7,578 | 14,239 |
| Right of use assets | 64,954 | 45,531 |
| Other non-current assets | 317,936 | 292,949 |
| Total assets | 3,128,366 | 3,147,974 |
| Current liabilities: | ||
| Accounts payable | 95,875 | 76,741 |
| Accrued expenses | 418,996 | 271,697 |
| Deferred revenue, current portion | 89,244 | 89,244 |
| Other current liabilities | 15,489 | 15,051 |
| Total current liabilities | 619,604 | 452,733 |
| Long-term debt | 1,544,292 | 1,096,876 |
| Lease liabilities, net of current portion | 57,578 | 41,512 |
| Deferred revenue, net of current portion | 485,000 | 574,244 |
| Contingent consideration | 36,900 | 43,600 |
| Other non-current liabilities | 42 | 11,000 |
| Total liabilities | 2,743,416 | 2,219,965 |
| Commitments and contingencies (Note 21) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding | 0 | 0 |
| Common stock, $0.0001 par value, 198,000,000 shares authorized; 87,950,117 and 87,126,974 issued and outstanding at December 31, 2022 and 2021, respectively | 9 | 9 |
| Additional paid-in capital | 4,296,841 | 4,134,768 |
| Accumulated other comprehensive loss, net of tax | (1,664) | (20) |
| Accumulated deficit | (3,910,236) | (3,206,748) |
| Total stockholders’ equity | 384,950 | 928,009 |
| Total liabilities and stockholders’ equity | $ 3,128,366 | $ 3,147,974 |